Please provide your email address to receive an email when new articles are posted on . In patients with atrial fibrillation, left atrial appendage closure was superior to anticoagulation for bleeding ...
While the age-specific analysis was welcome, some felt it didn’t dig deep enough and others questioned the bleeding endpoints ...
The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during ...
For patients with non-valvular atrial fibrillation (AFib) who had no contraindications to taking oral anticoagulants, the use of a device to close off the left atrial appendage in the heart—a small ...
The global left atrial appendage closure (LAAC) devices market is expected to witness substantial growth and is projected to expand at a CAGR of nearly 15% over the next five years. The increasing ...
Paris, France, 19−22 May 2026. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
Watchman isn’t hitting the mark for Boston Scientific. Weak demand for the Left Atrial Appendage (LAA) Closure Device, which was once a jewel in the Marlborough, MA-based company’s crown, sent shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results